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costs associated with the treatment of IBS in England. Methods: Hospital Episode 
Statistics (HES) data for 2012-13 for all clinical commissioning groups (CCGs) in 
England were analysed to calculate the tariff cost of IBS. IBS diagnosis codes were 
included in the analysis. Prescribing data and cost (PACT) data for 2012-13 were 
also analysed. Results: During 2012/13 there were 1,217,993 outpatient appoint-
ments in gastroenterology and colorectal surgery specialities, with a total tariff cost 
of £365,868,937. Despite this, only 1,982 patients were recorded with IBS-specific 
codes, with a total estimated tariff cost of £812,336. In addition, 28,849 patients 
were recorded with IBS-related symptom codes at a cost of £11,002,874. There were 
also 658,698 diagnostic lower GI endoscopies at a tariff cost of £169,676,704. Of 
these, 323,752 (49%) had no further follow-up in secondary care in the subsequent 
12 months. PACT data indicated that £44,977,959 and £25,582,752 was spent on 
selected laxatives and antispasmodics, respectively, commonly used to treat IBS in 
primary care. ConClusions: Despite being poorly clinically coded, it is clear that 
IBS places a significant cost burden on the NHS. Notably, 49% of patients seen for 
lower GI endoscopies had no further activity provided by the Hospital Provider Trust 
as an inpatient or outpatient over the subsequent 12 months, implying functional 
symptoms. Better diagnosis and subsequent management of IBS within a primary 
care setting may provide direct savings in the cost of IBS management. This study 
was financially supported by Almirall. Hospital Episode Statistics Data were pro-
vided via Harvey Walsh Ltd under commercial reuse licence.
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objeCtives: There are an estimated 620,000 patients with inflammatory bowel 
disease (IBD) in the UK. The rising incidence of IBD combined with its incurability 
has significant cost implications, with the National IBD Audit estimating that cost 
to the National Health Service (NHS) exceeded £1 billion in 2010. The aim of this 
cost of care model was to calculate the annual cost per patient of treating ulcerative 
colitis (UC) and Crohn’s disease (CD) from an NHS perspective, and to enable areas 
of potential cost savings to be explored. Methods: The cost of IBD was calculated 
by summing the costs of treatment, treatment side effects and disease-related com-
plications, accounting for the proportions of patients incurring these costs. The 
model included detailed costs for each treatment (eg. brand of mesalazine), major 
side effects for each treatment (eg. pancreatitis from thiopurines) and complica-
tions (eg. pyoderma gangrenosum). Default input values for costs, the percentage 
of patients receiving each treatment, and the percentage of patients experiencing 
side effects or complications were determined from national sources and published 
literature. However, the model permitted the user to input local or alternative data 
(eg. to reflect brand preferences for oral mesalazines) and conduct scenario analy-
ses. Results: Using default input values, the annual cost of treating any UC patient 
was estimated to be £3,084. For a UC patient in remission, in relapse with mild-to-
moderate UC or in relapse with severe UC, annual cost per patient was estimated 
to be £1,693, £2,903 and £10,760, respectively. The annual cost for any CD patient 
was estimated to be £6,156 (£1,800 for patients in remission; £10,513 for patients in 
relapse). ConClusions: IBD is a costly, chronic condition and this model facilitates 
calculation of annual costs per UC and CD patient. The models’ customisability will 
help hospitals to identify areas where savings could be made.
PGI18
heAlth CAre Cost AssoCIAted to ConstIPAtIon PredoMInAnt IrrItABle 
Bowel syndroMe In sPAIn
Raya A.1, Barrull C.2, Roset M.2, Cortes X.1, Fortea J.1
1Almirall S. A, Barcelona, Spain,, 2IMS Health, Barcelona, Spain
objeCtives: To estimate health care resource use and costs associated with the man-
agement and treatment of constipation predominant irritable bowel syndrome (IBS-C) 
in Spanish clinical practice. Methods: The 2011 primary care (PC) IASIST database, 
which includes 3,678,522 clinical charts corresponding to PC sites from the National 
Health System (NHS), was used to estimate the number of patients with IBS-C (identi-
fied by a combination of ICD code and prescription of IBS-C drugs) and obtain data 
on the number of hospitalizations (service, frequency and duration), scheduled and 
emergency visits to PC, referrals to specialist care, and IBS-C treatments prescribed 
and dispensed in retail pharmacies and their associated costs. Based on data from 
IASIST database and unit costs retrieved from the e-Salud database, health care costs 
associated with IBS-C from the NHS perspective were calculated. Results: A total of 
5,649 IBS-C patients were indentified in the database, corresponding to a prevalence 
of 0.15% of patients attending PC. Total costs associated with IBS-C in the sample were 
estimated to be € 4,755,725; highest costs were associated with PC visits (€ 2,791,725, 
corresponding to 58.7% of total IBS-C costs). This high cost of PC visits is explained by 
the high number of visits by IBS-C patients (17.4 visits annually per patient). Costs of 
PC visits are followed by hospitalization costs (€ 610,859, 12.8% of total cost), medical 
visits to specialists (€ 556,164, 11.7%) and emergency room visits to PC (€ 491,142,10.3%). 
Costs of pharmacological treatment (€ 305,707) represented only 6.4% of total IBS-C 
costs. ConClusions: The low prevalence of IBS-C observed may be due to the under-
registration or under-diagnosis of IBS-C. Costs associated with the management of 
IBS-C are driven mainly by the high number of PC visits, which may be associated 
with the current unmet medical needs in IBS-C.
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from $1,747 to $48,782 per patient year. Per patient episode, direct costs associated 
with OIC ranged from $54 to $11,705. This was further supported by a large inter-
national study which reported significantly more physician visits and alternative 
care provider visits among patients with OIC than those without OIC. Two studies 
reported on a subgroup of patients with OIC who failed to respond to laxatives; 
these patients reported higher direct costs than patients who had a response to 
laxatives. ConClusions: The management of OIC is associated with potentially 
significant health care resource utilisation and financial burden. Patients with OIC 
incur higher direct health care costs than those without OIC and costs are increased 
further if patients with OIC have failed to respond to laxatives. There remains a 
paucity of data on health care resource utilisation in OIC and further research into 
the economic burden of OIC is needed.
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objeCtives: This study is the first study to assess the burden of IBS-C in 6 European 
countries (France, Germany, Italy, Spain, Sweden, UK). Here we present the results 
for Spain. Methods: Observational, retrospective-prospective (6 months each) 
study in patients diagnosed with moderate-to-severe IBS-C in the last five years 
(Rome-III criteria). Moderate-to-severe IBS-C was defined as IBS-Symptom Severity 
Score (IBS-SSS) ≥ 175. Quality-of-life (QoL) was assessed with EuroQoL-5D (EQ-5D) 
and IBS-QoL. Results: 112 patients were included (58% severe, mean age (±SD) 
46.8±13.7 years, 86% female). At baseline, symptom severity (IBS-SSS; severe > 300) 
was 315.4±82.9; presenteeism (WPA: IBS-C questionnaire; mean [±SD] % time in 
week prior to inclusion): 32.3±27.2; absenteeism: 6.1±15.8; work productivity loss: 
29.2±27.5; and daily activity impairment 39.6±27.2. Mean IBS-QoL was 41.0±21.2, 
(scale: 0-100 [best-to-worst]), and the most affected domains were “food avoidance” 
(mean: 60.4) and “health worry” (54.6). Mean EQ-5D was 57±21 (scale: 0-100 [worst-
to-best]) and 86% and 63% of patients reported moderate-to-severe problems in 
pain/discomfort, anxiety/depression respectively. The most prevalent symptoms 
were: constipation (84%), abdominal pain (80%), abdominal distention (80%) and 
bloating (59%). Over the year, 88% of patients consulted a primary care physician, 
and 82% a gastroenterologist; mean (95%CI): 3.8 and 2.3 visits, respectively. 20% of 
patients required emergency department visits or hospitalization (mean stay: 1.5 
(0.6-2.4) days). 58% of patients underwent a diagnostic test (mean: 2.4 (1.8-2.9)). 
85% of patients took pharmacological medication (80% took some pharmacological 
medication for their IBS-C) 30% received complementary therapies. After 6 months 
of follow-up, only 1 in 5 patients had no or mild symptoms. The mean (95%CI) annual 
direct cost for the Spanish National Health System (NHS) was 1067€ (730-1447) and 
the mean cost for the patient was 568€ (333-841). 13% of patients took sick leave 
(mean: 6.3 times; mean duration: 52 days) and 28% had productivity losses (mean: 
55 hours). Mean indirect costs were 1362€ (313-2866). Total costs amounted to 2997€ 
(1799-4515) /year. ConClusions: Moderate-to-severe IBS-C has a great impact on 
patient QoL, productivity, and health care resource utilization.
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objeCtives: The burden and cost of liver disease is known to be substantial, but accu-
rate data on this subject is still scarce in Portugal. So far most estimates are obtained 
from diagnosis-related groups (DRGs) associated with hospital financing and from 
expert panels. In this analysis we aimed to calculate the real costs associated with 
hospital admissions due to liver cirrhosis (LC) in a large hospital. Methods: All hos-
pitalizations in the gastroenterology department from a tertiary hospital in Portugal 
(Centro Hospitalar Lisboa Central) during 2012 were analyzed. Patient level data was 
used to retrieve relevant demographic and clinical information. Costs assumed to be 
specific for LC admissions, namely medication, imaging and other techniques, were 
estimated directly. Department-specific hospital accountancy was used to include 
the remaining hospital costs associated with these hospitalizations. Results: A 
total of 644 admissions were analyzed, from which 135 (21.0%) were due to LC, cor-
responding to 82 patients. 74.4% (n= 61) were males, median age was 55 years. The 
main cause of LC was alcohol (58.5%). In the admissions due to LC, average length 
of stay (LoS) was 15.3 days and total mean hospitalization cost was 3,979.5€ . For all 
analyzed admissions, average LoS and mean total cost were 8.1 days and 2,323.8€ , 
respectively. Average cost for medications in admissions for LC amounted to 492.7€ , 
compared to 228.7€ for all admissions. Within admissions for LC, costs were not 
significantly different for hospitalizations with or without hepatocellular carci-
noma. ConClusions: The estimated overall cost of a hospital admission for LC in 
a gastroenterology department was superior to the average value of hospitalizations 
for all causes, and approximately twice the official DRG value. This study highlights 
the current economic burden of liver cirrhosis faced by a tertiary hospital and the pos-
sible need to revise some of the assumptions used for financing Portuguese hospitals.
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objeCtives: The NHS is faced with increasing cost pressures that make the effi-
cient use of resources paramount. Patients with IBS may consume considerable 
NHS resource through inpatient and outpatient visits, diagnostic tests and treat-
ment. This study aimed to estimate admission costs and primary care prescribing 
A366  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
PGI22
Cost-effeCtIveness AnAlysIs of A PersonAlIzed therAPy for GenotyPe 
1, nAIve, ChronIC hePAtItIs C PAtIents In ItAly
Iannazzo S.1, Colombatto P.2, Bonino F.2, Brunetto M.R.2
1SIHS Health Economics Consulting, Torino, Italy, 2University Hospital (AOUP), Cisanello (Pi), Italy
objeCtives: Rapid Virologic Response (RVR) is currently used as the best predictor 
of Sustained Virologic Response (SVR) with dual therapy (DT) in genotype-1 chronic 
hepatitis C (G1-CHC), to optimize the adoption of the triple therapy (TT) with 
direct-acting antivirals (boceprevir: BOC and telaprevir: TVR). Bio-mathematical 
modelling of viral dynamics during DT has potentially higher accuracy than RVR 
in the identification of SVR patients. The objective of this study was to analyse 
the cost-effectiveness profile of a personalized anti-HCV therapy in F0-F2 G1-CHC 
based on a bio-mathematical model (model-guided strategy: MG) rather than on 
the RVR (guideline-guided strategy: GG). Methods: A deterministic bio-math-
ematical model of the infected cell dynamics was validated in a cohort of 135 
G1-CHC patients treated with DT at the University Hospital in Pisa, Italy. A lifetime 
health economic (HE) model was then developed to compare MG and GG strategies 
in the perspective of the Italian National Health Service. The model was alimented 
with observed data in the validation cohort, clinical variables and economic 
data available in the literature. A 3.5% discount rate was applied to outcomes 
and costs. One-way and probabilistic sensitivity analyses were run. Results: 
The outcomes with MG- and GG-strategy were 19.1-19.4 and 18.9-19.3 quality-
adjusted-life-years (QALY). Total per-patient lifetime costs were € 25,200-€ 26,000 
with MG-strategy and € 28,800-€ 29,900 with GG-strategy. When comparing MG- 
with GG-strategy the former resulted more effective and less costly, being defined 
as dominant. ConClusions: The adoption of a SVR predictive criterion based 
on a bio-mathematical model, has the potential to improve the cost-effectiveness 
of a personalized anti-HCV therapy, allowing a more accurate identification of 
patients who can be effectively treated with DT and reserving high-cost BOC- and 
TVR-based TT for those who really need it.
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objeCtives: Pegylated interferon-α plus ribavirin (PR) has been the standard of 
care for Chronic Hepatitis C (CHC). Therapy adding boceprevir (BOC) or telaprevir 
(TVR) to PR in HCV genotype-1 patients has failed to achieve generalized market 
acceptance, in part due to the approval of newer more efficacious and safer options 
like sofosbuvir (SOF), a new pan-genotypic RNA-polymerase inhibitor. Objective: To 
assess the cost-effectiveness of sofosbuvir based therapy for CHC across HCV geno-
types, pretreatment conditions and HIV co-infection in Portugal. Methods: Costs 
and effectiveness were estimated based on discrete-time Markov-type model for 
CHC evolution accounting for different subpopulations in terms of HCV genotype, 
fibrosis progression, HIV co-infection status and previous treatment experience. 
The model incorporates 13 health states: 5 Metavir score, 2 SVR (with and without 
cirrhosis) and 3 advanced liver disease states (decompensated cirrhosis, hepatocel-
lular carcinoma, liver transplant). Results are expressed in incremental costs per 
life year (LY) and quality-adjusted life year (QALY). Results: Overall sofosbuvir-
containing regimens are expected to result in an increment of 3.49 LY (3.05 QALY) 
after weighting for the different subpopulations assuming Portuguese epidemiol-
ogy. The corresponding weighted incremental cost-effectiveness ratios (ICER) was 
14,649€ /LY (16,720€ /QALY). In the comparison against the BOC and TVR containing 
regimens (genotype-1), ICER of 10,675€ /LY (12,238€ /QALY) and 14,618€ /LY (16,495€ /
QALY) were obtained, respectively. For HIV co-infected and PegIFN eligible/tolerant 
patients, estimated ICER varied between 6,463€ /LY (6,902€ /QALY) and 21,281€ /LY 
(28,245€ /QALY), for G1 and G2, respectively, when comparing against treatment with 
PR. Additionally, in HCV/HIV coinfected patients ineligible/intolerant to PegIFN, the 
comparison against lack-of-therapy resulted in ICER of 15,656€ /LY (17,756€ /QALY) 
and 12,915€ /LY (19,077€ /QALY), for HCV G1 and G3, respectively. ConClusions: 
Sofosbuvir-containing regimens for the treatment of adult CHC patients, irrespec-
tive of HIV co-infection status, are expected to result in significant health gains at 
an incremental cost within the range of European Health Authorities acceptability.
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objeCtives: To evaluate the clinical and economic expediency of adding simeprevir 
(SMV) to pegylated-interferon and ribavirin (PR) versus PR only, or triple thera-
pies with PR plus boceprevir (BOC) or telaprevir (TVR) for treatment of genotype 
1 chronic hepatitis C (CHC) virus infection in patients who have failed previous 
therapy with interferon and ribavirin in Russia. Methods: A Markov model devel-
oped earlier was adapted to the Russian settings. The analysis consists of 2 time 
periods: 1st the antiviral therapy (AVT) phase and 24 week follow-up (0-72 weeks) 
and 2ndthe disease progression of CHC (72 weeks - lifetime). Incidences of disease 
progression health-states (decompensated cirrhosis, hepatocellular carcinoma, liver 
transplant, post-liver transplant and death, associated with high health care costs, 
high mortality rates) based on available published data. Costs and outcomes (life 
years, LY) were analyzed for treatment experienced CHC patients from Russian 
health care system perspective. The incremental cost-effectiveness ratio (ICER) per 
objeCtives: To estimate health care costs of alternative therapeutic strategies: 
no treatment versus peginterferon and ribavirin (PR) versus protease inhibi-
tor (PI) boceprevir added to PR for Russian treatment experienced chronic HCV 
patients, who had failure previous treatment, in short- and long-term time hori-
zon. Methods: An Excel-based model was developed to evaluate costs and 
outcomes of chronic HCV treated with dual therapy with PR and triple therapy 
with boceprevir in combination with PR. Costs for two time periods were ana-
lysed: antiviral therapy costs (0-48 weeks) and disease-progression related costs 
(from 48 weeks to 25 years), depending on the chosen therapy. Antiviral drug costs 
were calculated on the base of registered prices from the list of vital and essential 
drugs. Incidence of compensated and decompensated cirrhosis, hepatocellular 
carcinoma, liver transplant and post-liver transplant in the outcome of chronic 
HCV in long-term period was derived from available published data. Treatment 
costs of liver disease progression events were estimated according to the tariffs 
of the Russian health care system in 2014. Results: Boceprevir +PR compared 
to no treatment strategy and PR therapy was associated with more avoided 
liver-disease progression events at lesser costs, resulting in boceprevir+PR as 
the dominant treatment option in patients with chronic HCV genotype 1 non-
responders to previous treatment in Russia. Additional costs per avoided event of 
liver-disease progression for boceprevir plus PR and dual PR therapy were € 
12,654.26 and € 45,082.82 respectively. ConClusions: Antiviral therapy with 
boceprevir plus PR in comparison with only PR therapy and no treatment strat-
egy is cost effective due to reduced frequency of disease progression events and 
associated costs.
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objeCtives: The clinical efficacy of lubiprostone in chronic idiopathic constipa-
tion has been demonstrated in three randomised clinical trials (RCTs). This analy-
sis assesses the cost effectiveness of lubiprostone compared to prucalopride (the 
current standard of care), placebo and immediate referral to secondary care from 
the perspective of the UK National Health Service (NHS). Methods: A state-
transition model was constructed to represent the treatment pathway for chronic 
idiopathic constipation from an NHS perspective with a 1-year time horizon. The 
model considered treatment continuation rules, at Week 2 for lubiprostone and 
Week 4 for prucalopride. Clinical data were taken from RCTs and an indirect com-
parison with prucalopride. Long-term duration of treatment was estimated by fit-
ting curves to open-label study data. Costs included drug costs, medical resource 
use, and the cost of the pathway including primary and secondary care, obtained 
from published sources. Quality of life was modelled according to whether con-
stipation was resolved or unresolved, with values taken from a large published 
study (n= 1,200). Results: Compared to placebo, lubiprostone delayed referral to 
secondary care and improved quality of life, but resulted in increased costs due to 
treatment, the incremental cost-effectiveness ratio was £2,924. Lubiprostone and 
prucalopride were found to have similar efficacy, with lubiprostone generating an 
additional 0.0014 QALYs in the base case. The cost per day for lubiprostone is lower 
than for prucalopride; leading to lower total costs (£1,596 v £1,655), and meaning 
lubiprostone dominated prucalopride (lower cost and higher QALYs). Probabilistic 
sensitivity analysis showed lubiprostone to have an 84% chance of being the 
most cost-effective treatment at a threshold of £20,000 per QALY. ConClusions: 
Treatment with lubiprostone provides substantial value to both patients and the 
NHS, being highly cost effective compared to placebo and dominant compared to 
the current standard of care.
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objeCtives: Constipation-predominant irritable bowel syndrome (IBS-C) affects 
more than 2% of the population carrying a heavy burden in developed countries 
and leading to significant losses in patients’ quality of life. Treatment goals are 
to provide relief of abdominal pain, restore the bowel transit and alleviate associ-
ated symptoms. Linaclotide has been shown to significantly improve abdominal 
and bowel symptoms in two phase III trials being the only EMA approved therapy 
indicated for the treatment of IBS-C. Therefore, this study aimed to perform a 
cost-effectiveness analysis comparing linaclotide with no active treatment for 
the treatment of IBS-C from the Portuguese societal perspective. Methods: A 
Markov model was developed to simulate the natural course and treatment of the 
disease. Patient-level satisfaction data from linaclotide’s randomised clinical trials 
was used to define 4 health states: ‘Not Satisfied’, ‘Moderately Satisfied’, ‘Satisfied’ 
and ‘Dead’. These data were linked to utility scores based on patients’ responses 
to the EuroQol-5D questionnaire. Transitions between health states were assumed 
to occur every 4 weeks, with probabilities derived from observed efficacy data 
up to 20-weeks. Extrapolation beyond this period was based on last observation 
carried forward data. Effectiveness was measured in quality-adjusted life years 
(QALY). Only direct costs were incorporated. Resource utilization was estimated 
from a literature review. Unit costs came from official Portuguese databases and 
pricing lists. Time horizon was fixed at 10 years. Probabilistic sensitivity analy-
sis was conducted with Monte Carlo simulations. Results: A mean gain of 0.22 
QALY (95%CI: [0.1; 0.35]) was estimated for each patient treated with linaclotide 
versus no treatment. Additionally, linaclotide utilization led to an overall aver-
age cost reduction of 402€ (95%CI: [-1,735; 536]) thus representing a dominant 
option. ConClusions: When compared with no active treatment, linaclotide 
is a cost-saving and more effective therapeutic option for the treatment of IBS-C 
from the Portuguese societal perspective.
